Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 2/20 | 0.72 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.72 |
| ▸ | MEN1 | O00255 | 1/20 | 0.67 |
| ▸ | GLA | P06280 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.67 |
| ▸ | TSHR | P16473 | 2/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | KDM1A | O60341 | 5/20 | 0.56 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.50 |
| ▸ | SAT1 | P21673 | 2/20 | 0.48 |
| ▸ | S1PR2 | O95136 | 5/20 | 0.41 |
| ▸ | S1PR4 | O95977 | 5/20 | 0.41 |
| ▸ | S1PR1 | P21453 | 5/20 | 0.41 |
| ▸ | S1PR3 | Q99500 | 5/20 | 0.41 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.41 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13097540 | 0.97 | CYP2C19 (0.77) | CYP2C19CYP1A2MEN1GLAKMT2A | |
| SCHEMBL15884078 | 0.97 | CYP2C19 (0.77) | CYP2C19CYP1A2MEN1GLAKMT2A | |
| SCHEMBL24409456 | 0.97 | CYP2C19 (0.77) | CYP2C19CYP1A2MEN1GLAKMT2A | |
| SCHEMBL5183955 | 0.94 | CYP2C19 (0.82) | CYP2C19CYP1A2MEN1GLAKMT2A | |
| SCHEMBL5172702 | 0.91 | CYP2C19 (0.81) | CYP2C19CYP1A2MEN1GLAKMT2A | |
| SCHEMBL997030 | 0.91 | CYP2C19 (0.81) | CYP2C19CYP1A2MEN1GLAKMT2A | |
| SCHEMBL11508516 | 0.91 | TSHR (0.69) | CYP2C19CYP1A2MEN1GLAKMT2A | |
| SCHEMBL7097560 | 0.91 | CYP2C19 (0.87) | CYP2C19CYP1A2MEN1GLAKMT2A | |
| SCHEMBL7091884 | 0.91 | CYP2C19 (0.87) | CYP2C19CYP1A2MEN1GLAKMT2A | |
| SCHEMBL1248078 | 0.91 | TSHR (0.69) | CYP2C19CYP1A2MEN1GLAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240024318-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-01-25 | — | — | US | disclosed |
| US-11679109-B2 | SMARCA degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-06-20 | — | — | US | disclosed |
| US-20220340570-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2022-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240024318-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCA2, SMARCC2 | CYP2C19 3201/4885CYP1A2 1657/4885MEN1 2085/4885 |
| US-20220340570-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | CYP2C19 3990/4885CYP1A2 3570/4885MEN1 4055/4885 |
| US-11679109-B2 | SMARCA degraders and uses thereof | SMARCA1, SMARCA2, SMARCC2 | CYP2C19 3201/4885CYP1A2 1657/4885MEN1 2085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.